US Bancorp’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.69K Buy
+547
New +$2.94K ﹤0.01% 3858
2024
Q4
– Sell
-27,244
Closed -$128K – 4272
2024
Q3
$128K Sell
27,244
-1,143
-4% -$6.13K ﹤0.01% 2276
2024
Q2
$160K Hold
28,387
– – ﹤0.01% 2106
2024
Q1
$117K Sell
28,387
-2,529
-8% -$10.1K ﹤0.01% 2277
2023
Q4
$130K Buy
30,916
+30,555
+8,464% +$123K ﹤0.01% 2223
2023
Q3
$1.56K Sell
361
-2,607
-88% -$14.5K ﹤0.01% 3699
2023
Q2
$19.6K Buy
2,968
+2,607
+722% +$16.7K ﹤0.01% 2989
2023
Q1
$2.45K Sell
361
-138
-28% -$970 ﹤0.01% 3705
2022
Q4
$3.69K Hold
499
– – ﹤0.01% 3616
2022
Q3
$5K Sell
499
-1,032
-67% -$10.9K ﹤0.01% 3626
2022
Q2
$17K Buy
1,531
+480
+46% +$4.97K ﹤0.01% 3153
2022
Q1
$12K Buy
1,051
+844
+408% +$11.1K ﹤0.01% 3320
2021
Q4
$3K Hold
207
– – ﹤0.01% 3837
2021
Q3
$4K Sell
207
-639
-76% -$11.2K ﹤0.01% 3735
2021
Q2
$18K Hold
846
– – ﹤0.01% 3202
2021
Q1
$13K Buy
846
+400
+90% +$6.48K ﹤0.01% 3205
2020
Q4
$6K Sell
446
-478
-52% -$5.75K ﹤0.01% 3369
2020
Q3
$9K Sell
924
-611
-40% -$6.53K ﹤0.01% 3128
2020
Q2
$17K Sell
1,535
-514
-25% -$5.82K ﹤0.01% 2896
2020
Q1
$22K Sell
2,049
-1,213
-37% -$15K ﹤0.01% 2714
2019
Q4
$53K Sell
3,262
-3,364
-51% -$50.9K ﹤0.01% 2456
2019
Q3
$88K Sell
6,626
-19,741
-75% -$275K ﹤0.01% 2226
2019
Q2
$372K Sell
26,367
-13,686
-34% -$218K ﹤0.01% 1548
2019
Q1
$737K Buy
40,053
+6,845
+21% +$156K ﹤0.01% 1207
2018
Q4
$868K Buy
33,208
+6,118
+23% +$144K ﹤0.01% 1084
2018
Q3
$621K Buy
27,090
+26,782
+8,695% +$547K ﹤0.01% 1343
2018
Q2
$6K Buy
308
+148
+93% +$2.48K ﹤0.01% 3291
2018
Q1
$3K Sell
160
-3,064
-95% -$51.3K ﹤0.01% 3438
2017
Q4
$49K Buy
3,224
+2,924
+975% +$43.4K ﹤0.01% 2613
2017
Q3
$5K Hold
300
– – ﹤0.01% 3276
2017
Q2
$5K Hold
300
– – ﹤0.01% 3239
2017
Q1
$4K Buy
+300
New +$4.28K ﹤0.01% 3275

Other funds holding VNDA

US Bancorp's VNDA Position: Q3 2026 in Review

US Bancorp opened a new position in Vanda Pharmaceuticals (VNDA) in Q3 2026: 547 shares worth $2.69K. The stake represents ﹤0.01% of the portfolio and ranks #3858 among its holdings. This is a return to the name: US Bancorp previously reported a position in VNDA as recently as Q3 2024.

US Bancorp first reported a position in VNDA in Q1 2017 and has held it in 32 quarters since. The position peaked at $868K in Q4 2018. 150 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • US Bancorp held 547 shares of Vanda Pharmaceuticals worth $2.69K as of Q3 2026.
  • Vanda Pharmaceuticals was a new US Bancorp position in Q3 2026.
  • Vanda Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #3858 holding.
  • US Bancorp first reported a position in Vanda Pharmaceuticals in Q1 2017 and has held it in 32 quarters since.
  • US Bancorp's Vanda Pharmaceuticals position peaked at $868K in Q4 2018.
  • 150 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.